Pomerantz Gets Lead Role As Juno Investor Class Certified
Investors claiming the immunotherapy company Juno Therapeutics failed to inform them of the health risks associated with one of its drugs received class certification on Tuesday in Washington federal court, and...To view the full article, register now.
Already a subscriber? Click here to view full article